<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03521505</url>
  </required_header>
  <id_info>
    <org_study_id>201601093A3</org_study_id>
    <nct_id>NCT03521505</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine for Sedation of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration</brief_title>
  <official_title>Dexmedetomidine and Brain Perfusion Monitor for Sedation of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preventing hypoxemia is one of the major goal of studies for bronchoscopic sedation.&#xD;
      Dexmedetomidine is a sedative agents via α2 adrenergic agonist, with little respiratory&#xD;
      suppression. In the preset study, we evaluate the safety and feasibility of the&#xD;
      Dexmedetomidine in the specific bronchoscopic procedure, endobronchial ultrasound&#xD;
      (EBUS)-guided transbronchial needle aspiration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing flexible bronchoscopy (FB) experience procedure-related symptoms. Current&#xD;
      guidelines of FB recommend sedation to all patients undergoing FB, except when there are&#xD;
      contraindications. Propofol plus an opioid is the common combination used to improve patient&#xD;
      tolerance and satisfaction during FB. However, controversy about combining propofol and&#xD;
      opioids persists because of the risk of over-sedation and cardiopulmonary depression,&#xD;
      especially for the time-consuming endobronchial ultrasound (EBUS)-guided transbronchial&#xD;
      needle aspiration (TBNA). Similar with other published data, around 40% of hypoxemia event&#xD;
      was observed during FB sedation in the investigators' hospital. Dexmedetomidine, is a&#xD;
      sedative agents via α2 adrenergic agonist, with little respiratory suppression. It has been&#xD;
      applied in patients with mechanical ventilation, undergoing gastroendoscopy and extracorporal&#xD;
      shockwave lithotripsy. Little evidences are available for Dexmedetomidine in sedation for&#xD;
      EBUS-TBNA.&#xD;
&#xD;
      In this study, the investigators will evaluate the safety and feasibility of Dexmedetomidine&#xD;
      for sedation of EBUS-TBNA comparing to Propofol for sedation of EBUS-TBNA. Generally, the FB&#xD;
      sedation can divided into three parts: the induction (from starting sedative administration&#xD;
      to insertion of bronchoscope); the maintenance ( from insertion of bronchoscope to its&#xD;
      removal) and the recovery (from bronchoscope removal to patients gain consciousness). The&#xD;
      primary endpoint is the proportion of patients with hypoxemia during maintenance of sedation.&#xD;
      the investigators will also observe the other sedative outcomes, e.g. blood pressure,&#xD;
      sedative drug dosing and patient tolerance and cooperation. The present study will also&#xD;
      observe the association between brain perfusion and sedative outcomes via non-invasive&#xD;
      monitor. Based on the unique pharmacokinetic property of Dexmedetomidine and the real-time&#xD;
      brain perfusion monitor, Dexmedetomidine-based sedation may provide better safety profile for&#xD;
      EBUS-TBNA than propofol and discover novel connection between sedative outcomes and brain&#xD;
      perfusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 11, 2018</start_date>
  <completion_date type="Actual">January 22, 2020</completion_date>
  <primary_completion_date type="Actual">January 22, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hypoxemia During Maintenance</measure>
    <time_frame>After starting bronchoscopy, up to 120 minutes</time_frame>
    <description>The percentage of patients with hypoxemia (oxyhemoglobin saturation (SpO2)&lt;90%) during maintenance of Bronchoscopic sedation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoxemia During Induction</measure>
    <time_frame>After starting induction, up to 30 minutes.</time_frame>
    <description>The percentage of patients with hypoxemia (oxyhemoglobin saturation (SpO2)&lt;90%) during induction of bronchoscopic sedation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Global Tolerance for Bronchoscopy</measure>
    <time_frame>After recovery from sedation, up to 120 minutes</time_frame>
    <description>The Global Tolerance of patients for bronchoscopy will be evaluated by 100-mm visual analogue scale (VAS, 0: no bother, 100: worst intolerable) after recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Cooperation of Patients From the View of Bronchoscopists</measure>
    <time_frame>After recovery from sedation, up to 120 minutes</time_frame>
    <description>The Cooperation of Patients will be evaluated by 100-mm visual analogue scale (VAS, 0: well cooperation, 100: worst cooperation) after recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypotension During Bronchoscopic Sedation</measure>
    <time_frame>After starting sedation, up to 120 minutes.</time_frame>
    <description>The percentage of patients with hypotension (mean arterial blood pressure (MAP) less than 65 mmHg with any duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bradycardia During Bronchoscopic Sedation</measure>
    <time_frame>After starting sedation, up to 120 minutes.</time_frame>
    <description>The percentage of patients with bradycardia (heat beat per minute less than 60)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Time and Recovery Time</measure>
    <time_frame>After starting bronchoscopy, up to 120 minutes.</time_frame>
    <description>The procedure time of bronchoscopy and recovery time from sedation to awake.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Bronchoscopy</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine will be administrated for sedation of EBUS-TBNA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol will be administrated for sedation of EBUS-TBNA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine arm</intervention_name>
    <description>Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration</description>
    <arm_group_label>Dexmedetomidine arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol arm</intervention_name>
    <description>5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3~2.&#xD;
Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration.</description>
    <arm_group_label>Propofol arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing elective bronchoscopy and sedation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 20 years&#xD;
&#xD;
          -  American Society of Anaesthesiologists (ASA) physical status classification IV or V&#xD;
&#xD;
          -  Mallampati score of 4&#xD;
&#xD;
          -  Severe sleep apnoea syndrome (apnoea-hypopnea index more than 40)&#xD;
&#xD;
          -  Body mass index more than 42 in males or 35 in females&#xD;
&#xD;
          -  Neurologic disorders or other conditions contributing to difficulty in assessing&#xD;
             response&#xD;
&#xD;
          -  Forced expiratory vital capacity (FVC) less than 15 ml/kg body weight, forced&#xD;
             expiratory volume in one second (FEV1) less than 1000 ml, or FEV1/FVC less than 35%&#xD;
&#xD;
          -  History of second or third degree atrioventricular block, heat rate less than 50 beat&#xD;
             per minute or systolic blood pressure less than 90 mmHg&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients with a known history of allergy to the study drugs, or to eggs, soybeans or&#xD;
             sulfite products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ting-Yu Lin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Thoracic Medicine, Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Lin TY, Lo YL, Hsieh CH, Ni YL, Wang TY, Lin HC, Wang CH, Yu CT, Kuo HP. The potential regimen of target-controlled infusion of propofol in flexible bronchoscopy sedation: a randomized controlled trial. PLoS One. 2013 Apr 24;8(4):e62744. doi: 10.1371/journal.pone.0062744. Print 2013.</citation>
    <PMID>23638141</PMID>
  </reference>
  <reference>
    <citation>Lo YL, Lin TY, Fang YF, Wang TY, Chen HC, Chou CL, Chung FT, Kuo CH, Feng PH, Liu CY, Kuo HP. Feasibility of bispectral index-guided propofol infusion for flexible bronchoscopy sedation: a randomized controlled trial. PLoS One. 2011;6(11):e27769. doi: 10.1371/journal.pone.0027769. Epub 2011 Nov 23.</citation>
    <PMID>22132138</PMID>
  </reference>
  <reference>
    <citation>Lin TY, Fang YF, Huang SH, Wang TY, Kuo CH, Wu HT, Kuo HP, Lo YL. Capnography monitoring the hypoventilation during the induction of bronchoscopic sedation: A randomized controlled trial. Sci Rep. 2017 Aug 17;7(1):8685. doi: 10.1038/s41598-017-09082-8.</citation>
    <PMID>28819181</PMID>
  </reference>
  <reference>
    <citation>Ryu JH, Lee SW, Lee JH, Lee EH, Do SH, Kim CS. Randomized double-blind study of remifentanil and dexmedetomidine for flexible bronchoscopy. Br J Anaesth. 2012 Mar;108(3):503-11. doi: 10.1093/bja/aer400. Epub 2011 Dec 15.</citation>
    <PMID>22174346</PMID>
  </reference>
  <results_reference>
    <citation>Lin TY, Huang YC, Kuo CH, Chung FT, Lin YT, Wang TY, Lin SM, Lo YL. Dexmedetomidine sedation for endobronchial ultrasound-guided transbronchial needle aspiration, a randomised controlled trial. ERJ Open Res. 2020 Nov 10;6(4). pii: 00064-2020. doi: 10.1183/23120541.00064-2020. eCollection 2020 Oct.</citation>
    <PMID>33693047</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>April 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <results_first_submitted>February 19, 2021</results_first_submitted>
  <results_first_submitted_qc>August 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2021</results_first_posted>
  <last_update_submitted>August 15, 2021</last_update_submitted>
  <last_update_submitted_qc>August 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Ting-Yu Lin</investigator_full_name>
    <investigator_title>Medical doctor, Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Sedation</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>brain perfusion</keyword>
  <keyword>bronchoscopy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03521505/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from chest physicians referral at a medical center between and . The first participant was enrolled in May 2018 and the last participant was enrolled in January 2020.</recruitment_details>
      <pre_assignment_details>50 subjects met inclusion criteria and were randomized to treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dexmedetomidine Arm</title>
          <description>Dexmedetomidine will be administrated for sedation of EBUS-TBNA&#xD;
Dexmedetomidine arm: Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration</description>
        </group>
        <group group_id="P2">
          <title>Propofol Arm</title>
          <description>Propofol will be administrated for sedation of EBUS-TBNA&#xD;
Propofol arm: 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3~2.&#xD;
Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexmedetomidine Arm</title>
          <description>Dexmedetomidine will be administrated for sedation of EBUS-TBNA&#xD;
Dexmedetomidine arm: Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration</description>
        </group>
        <group group_id="B2">
          <title>Propofol Arm</title>
          <description>Propofol will be administrated for sedation of EBUS-TBNA&#xD;
Propofol arm: 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3~2.&#xD;
Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.7" spread="14.1"/>
                    <measurement group_id="B2" value="59.4" spread="12.2"/>
                    <measurement group_id="B3" value="59.5" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.6" spread="3.9"/>
                    <measurement group_id="B2" value="23.6" spread="3.8"/>
                    <measurement group_id="B3" value="23.6" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>American Society of Anaesthesiologists physical status</title>
          <description>The American Society of Anesthesiologists physical status classification system is a grading system for assessing the fitness of patients before surgery.&#xD;
A sixth category was later added. The higher grade, the poor physical status.&#xD;
Normal healthy patient;&#xD;
Patients with mild systemic disease&#xD;
Patients with severe systemic disease&#xD;
Patients with severe systemic disease that is a constant threat to life&#xD;
Moribund patients who are not expected to survive without the operation&#xD;
A declared brain-dead patient who organs are being removed for donor purposes</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B2" value="3" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B3" value="3" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mallampati score</title>
          <description>Mallampati score comprises a visual assessment of the distance from the tongue base to the roof of the mouth, and therefore the amount of space in which there is to work. There are 4 scores. The higher score represents narrower space of upper airway.&#xD;
Class I: Soft palate, uvula, fauces, pillars visible. Class II: Soft palate, major part of uvula, fauces visible. Class III: Soft palate, base of uvula visible. Class IV: Only hard palate visible.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B2" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B3" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hypoxemia During Maintenance</title>
        <description>The percentage of patients with hypoxemia (oxyhemoglobin saturation (SpO2)&lt;90%) during maintenance of Bronchoscopic sedation</description>
        <time_frame>After starting bronchoscopy, up to 120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine Arm</title>
            <description>Dexmedetomidine will be administrated for sedation of EBUS-TBNA&#xD;
Dexmedetomidine arm: Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration</description>
          </group>
          <group group_id="O2">
            <title>Propofol Arm</title>
            <description>Propofol will be administrated for sedation of EBUS-TBNA&#xD;
Propofol arm: 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3~2.&#xD;
Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoxemia During Maintenance</title>
          <description>The percentage of patients with hypoxemia (oxyhemoglobin saturation (SpO2)&lt;90%) during maintenance of Bronchoscopic sedation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoxemia During Induction</title>
        <description>The percentage of patients with hypoxemia (oxyhemoglobin saturation (SpO2)&lt;90%) during induction of bronchoscopic sedation</description>
        <time_frame>After starting induction, up to 30 minutes.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine Arm</title>
            <description>Dexmedetomidine will be administrated for sedation of EBUS-TBNA&#xD;
Dexmedetomidine arm: Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration</description>
          </group>
          <group group_id="O2">
            <title>Propofol Arm</title>
            <description>Propofol will be administrated for sedation of EBUS-TBNA&#xD;
Propofol arm: 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3~2.&#xD;
Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoxemia During Induction</title>
          <description>The percentage of patients with hypoxemia (oxyhemoglobin saturation (SpO2)&lt;90%) during induction of bronchoscopic sedation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Global Tolerance for Bronchoscopy</title>
        <description>The Global Tolerance of patients for bronchoscopy will be evaluated by 100-mm visual analogue scale (VAS, 0: no bother, 100: worst intolerable) after recovery</description>
        <time_frame>After recovery from sedation, up to 120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine Arm</title>
            <description>Dexmedetomidine will be administrated for sedation of EBUS-TBNA&#xD;
Dexmedetomidine arm: Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration</description>
          </group>
          <group group_id="O2">
            <title>Propofol Arm</title>
            <description>Propofol will be administrated for sedation of EBUS-TBNA&#xD;
Propofol arm: 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3~2.&#xD;
Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration.</description>
          </group>
        </group_list>
        <measure>
          <title>The Global Tolerance for Bronchoscopy</title>
          <description>The Global Tolerance of patients for bronchoscopy will be evaluated by 100-mm visual analogue scale (VAS, 0: no bother, 100: worst intolerable) after recovery</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="0" upper_limit="96"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Cooperation of Patients From the View of Bronchoscopists</title>
        <description>The Cooperation of Patients will be evaluated by 100-mm visual analogue scale (VAS, 0: well cooperation, 100: worst cooperation) after recovery.</description>
        <time_frame>After recovery from sedation, up to 120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine Arm</title>
            <description>Dexmedetomidine will be administrated for sedation of EBUS-TBNA&#xD;
Dexmedetomidine arm: Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration</description>
          </group>
          <group group_id="O2">
            <title>Propofol Arm</title>
            <description>Propofol will be administrated for sedation of EBUS-TBNA&#xD;
Propofol arm: 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3~2.&#xD;
Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration.</description>
          </group>
        </group_list>
        <measure>
          <title>The Cooperation of Patients From the View of Bronchoscopists</title>
          <description>The Cooperation of Patients will be evaluated by 100-mm visual analogue scale (VAS, 0: well cooperation, 100: worst cooperation) after recovery.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="0" upper_limit="87"/>
                    <measurement group_id="O2" value="31" lower_limit="1" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypotension During Bronchoscopic Sedation</title>
        <description>The percentage of patients with hypotension (mean arterial blood pressure (MAP) less than 65 mmHg with any duration.</description>
        <time_frame>After starting sedation, up to 120 minutes.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine Arm</title>
            <description>Dexmedetomidine will be administrated for sedation of EBUS-TBNA&#xD;
Dexmedetomidine arm: Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration</description>
          </group>
          <group group_id="O2">
            <title>Propofol Arm</title>
            <description>Propofol will be administrated for sedation of EBUS-TBNA&#xD;
Propofol arm: 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3~2.&#xD;
Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypotension During Bronchoscopic Sedation</title>
          <description>The percentage of patients with hypotension (mean arterial blood pressure (MAP) less than 65 mmHg with any duration.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bradycardia During Bronchoscopic Sedation</title>
        <description>The percentage of patients with bradycardia (heat beat per minute less than 60)</description>
        <time_frame>After starting sedation, up to 120 minutes.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine Arm</title>
            <description>Dexmedetomidine will be administrated for sedation of EBUS-TBNA&#xD;
Dexmedetomidine arm: Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration</description>
          </group>
          <group group_id="O2">
            <title>Propofol Arm</title>
            <description>Propofol will be administrated for sedation of EBUS-TBNA&#xD;
Propofol arm: 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3~2.&#xD;
Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Bradycardia During Bronchoscopic Sedation</title>
          <description>The percentage of patients with bradycardia (heat beat per minute less than 60)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Time and Recovery Time</title>
        <description>The procedure time of bronchoscopy and recovery time from sedation to awake.</description>
        <time_frame>After starting bronchoscopy, up to 120 minutes.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine Arm</title>
            <description>Dexmedetomidine will be administrated for sedation of EBUS-TBNA&#xD;
Dexmedetomidine arm: Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration</description>
          </group>
          <group group_id="O2">
            <title>Propofol Arm</title>
            <description>Propofol will be administrated for sedation of EBUS-TBNA&#xD;
Propofol arm: 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3~2.&#xD;
Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Time and Recovery Time</title>
          <description>The procedure time of bronchoscopy and recovery time from sedation to awake.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" spread="13.2"/>
                    <measurement group_id="O2" value="27.6" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>After subjects recovered from sedation, up to 30 minutes.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dexmedetomidine Arm</title>
          <description>Dexmedetomidine will be administrated for sedation of EBUS-TBNA&#xD;
Dexmedetomidine arm: Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration</description>
        </group>
        <group group_id="E2">
          <title>Propofol Arm</title>
          <description>Propofol will be administrated for sedation of EBUS-TBNA&#xD;
Propofol arm: 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3~2.&#xD;
Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 &lt; 90%) or hypotension (mean arterial pressure (MAP) &lt; 65 mmHg, or systolic blood pressure (SBP) &lt; 90 mmHg) in any duration.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nausia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Ting-Yu Lin</name_or_title>
      <organization>Chang-Gung Memorial Hospital</organization>
      <phone>886 3281200 ext 8467</phone>
      <email>yuebaoyuebao@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

